Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential TherapyHidekatsu Kuroda, Yasuhiro Takikawa, Takayoshi Oikawa et al.|Liver Cancer|2022Cited by 45
Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, JapanMasashi Fujita, Hiromasa Ohira, Kazumichi Abe et al.|Scientific Reports|2022Cited by 17
Abstracts from Japanese Journal of Hygiene (Nihon Eiseigaku Zasshi) Vol.51 No.2Suketami Tominaga, Seikou Ohta, Toshio Takeda et al.|Environmental Health and Preventive Medicine|1996Cited by 0